Evotec SE Names Dr Christian Wojczewski as New CEO

• Evotec SE has appointed Dr Christian Wojczewski as the new Chief Executive Officer, effective from 1st July 2024.
• The election was unanimous and followed an extensive selection process that began in January.
• Dr Mario Polywka, who has been serving as Interim CEO since 3rd January 2024, will retire at the end of June and will not seek re-election for his dormant Supervisory Board mandate.
• Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of experience in various management positions, most recently as CEO of Mediq and at Linde Healthcare.
• Dr Wojczewski has a track record of transforming companies and building high-performing life science organisations.
• Evotec SE is a life science company that provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, and other healthcare stakeholders.

The next important date, Business report 2023 and webcast, at Evotec is on 24.04.2024.

The price of Evotec at the time of the news was 14,235EUR and was up +3,72 % compared with the previous day.
14 minutes after the article was published, the price was 14,260EUR this corresponds to a plus of +0,18 % since publication.
At this time, the index MDAX was at 26.671,10PKT (+1,07 %).

Evotec

-2,13 %

+5,90 %

-31,27 %

-26,13 %

-40,17 %

-71,71 %

-55,47 %

+174,47 %

+1.079,22 %

ISIN:DE0005664809WKN:566480

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max